Lamivudine/Zidovudine

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

TreatmentEffectiveness

350 competitors in Treatment

#DrugCompanyPhaseTrials

1

Dexilant

Takeda

Preclinical

22

Niclocide

Bayer

Preclinical

13

Alfenta

Jazz Pharmaceuticals

Preclinical

14

Foscavir

CClinigen, Inc.

Preclinical

65

Valium

Akero Therapeutics

Preclinical

26

Clomid

Ferring

Preclinical

17

Aurlumyn

BBTG International Inc.

Preclinical

18

Reminyl

WWim Janssens

Preclinical

19

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

110

Lotemax

PPharmos

Preclinical

1Show 29 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Effectiveness8 trials

Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

Suspended·AAgouron Pharmaceuticals·Phase 2·NCT00004998·30 enrolled

A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000916·399 enrolled

A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults

Completed·GSK·Phase 4·NCT00004585·40 enrolled

Show 5 more trials

Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)

Unknown status·GSK·Phase 3·NCT00004981·230 enrolled

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000896·24 enrolled

Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006441·398 enrolled

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

Unknown status·AAgouron Pharmaceuticals·Phase 3·NCT00005002·688 enrolled

Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients

Suspended·AAgouron Pharmaceuticals·Phase 2·NCT00004999·350 enrolled

Treatment6 trials

Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00120510·816 enrolled

The Effect of Teaching HIV-Infected Patients About HIV and Treatment

Completed·GSK·Phase 3·NCT00002409·200 enrolled

Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected People in Wenxi County, Shanxi Province, China

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00100594·100 enrolled

Show 3 more trials

Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00100568·44 enrolled

A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment

Completed·GSK·N/A·NCT00002216

Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000903·444 enrolled

Drug5 trials

Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00014937·240 enrolled

A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients

Completed·GSK·Phase 4·NCT00005106·230 enrolled

A Study of Two Anti-HIV Drug Combinations

Completed·GSK·N/A·NCT00002203

Show 2 more trials

A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs

Completed·GSK·N/A·NCT00002217

Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen

Completed·Bristol-Myers Squibb·Phase 3·NCT00002429·500 enrolled

Pregnancy3 trials

Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

Completed·WWestat·Phase 4·NCT01618305·408 enrolled

SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women

Completed·SSt Stephens Aids Trust·Phase 1·NCT02499874·26 enrolled

Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00099632·484 enrolled

HIV3 trials

Study of Anti-HIV Therapy Intensification

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00034086·22 enrolled

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

Completed·GSK·Phase 4·NCT00005764·100 enrolled

A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001094

14 more indications

HIV infection3 trials

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000919·900 enrolled

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00017719·440 enrolled

Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00013520·1,125 enrolled

LAM2 trials

Zidovudine and Lamivudine Given Once Versus Twice Daily

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00014014·20 enrolled

A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine

Completed·Bristol-Myers Squibb·Phase 3·NCT00013897

Treatment Failure1 trial

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000918·300 enrolled

Tenofovir Disoproxil Fumarate1 trial

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

Completed·Gilead·Phase 3·NCT00112047·517 enrolled

Prospective1 trial

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 4·NCT00084136·1,571 enrolled

Immune System1 trial

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001119·288 enrolled

Toxicities1 trial

Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects

Completed·AAbbott·Phase 2·NCT00043953·30 enrolled

Prevention1 trial

Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00270296·730 enrolled

Tics1 trial

Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid

Unknown status·SSt Stephens Aids Trust·Phase 1·NCT02832778·35 enrolled

Intensive Care1 trial

Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00028327·250 enrolled

Safety and Efficacy1 trial

A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.

Completed·GSK·Phase 3·NCT00002199·550 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients

Completed·AAbbott·Phase 3·NCT00234923·138 enrolled

Combination Therapy1 trial

Study of Options for Second-Line Effective Combination Therapy (SELECT)

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 3·NCT01352715·515 enrolled

Child1 trial

Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00086359·19 enrolled

Details

Drug Info

Related News